Inhibiting PDH via more traditional approaches than are available for Myc could prove to be of enormous therapeutic benefit for the treatment of NAFLD, a common condition associated with considerable non-neoplastic morbidity and mortality as well being a significant predisposing factor for the development of cancer (257). The gene discussed is MYC; the disease is metabolic dysfunction-associated steatotic liver disease.